Skip to main content

Table 1 Cox analysis of the association between SPEN mutation and overall survival

From: Pan-cancer analysis identifies SPEN mutation as a predictive biomarker with the efficacy of immunotherapy

Variables

Univariable analysis

Multivariable analysis

HR

95% CI

P value

HR

95% CI

P value

Age (> 60 vs ≤ 60)

0.94

0.84–1.05

0.296

0.95

0.84–1.07

0.351

Gender (male vs female)

0.94

0.84–1.04

0.244

0.92

0.81–1.04

0.166

Cancer type

 Melanoma

1.00

Reference

 

1.00

Reference

 

 Lung cancer

1.37

(1.20–1.57)

< 0.001

1.38

(1.17–1.63)

< 0.001

 Other cancer

1.50

(1.32–1.70)

< 0.001

1.43

(1.22–1.67)

< 0.001

Treatment (combo vs mono)

0.61

0.50–0.75

< 0.001

0.59

(0.48–0.73)

< 0.001

TMB (> median vs ≤ median)

0.73

0.65–0.82

< 0.001

0.79

(0.70–0.90)

< 0.001

SPEN (Mutation vs Wild)

0.74

0.59–0.93

0.010

0.70

(0.51–0.95)

0.023